Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Sponsor
Hebei Medical University
Study ID
NCT05385185
Phase
PHASE2
Status
Unknown

Conditions

  • Endostatin
  • Immune Checkpoint Inhibitor
  • Leptomeningeal Metastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe

Key Dates

Start date
May 1, 2022
Status verified
May 2022
Primary completion
May 3, 2024
Completion
Dec 3, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Leptomeningeal metastases received PD-1 inhibitor and recombinant human endostatin
    Camrelizumab 200mg intravenously, once every 21 days or envafolimab 150mg subcutaneous injection,once a week Endostatin 30mg/d was administered intravenously for 7 days (d1-d7). The interval between Endostatin and next was 2 weeks.

Primary Outcome Measure

3-month overall survival rate [ Time Frame: 3 month ]

Central Contacts

Related Studies